ProMIS Neurosciences Stock Surges on Upcoming Alzheimer's Data Catalyst

ProMIS Neurosciences shares surged as investors await a pivotal 2026 data readout for its Alzheimer's candidate PMN310, which targets toxic oligomers to potentially reduce side effects.

Shares in biotechnology firm ProMIS Neurosciences soared over 12% on Friday, closing at €9.85, as investors anticipate a pivotal data readout for its Alzheimer's disease candidate. This sharp uptick marks a reversal from the stock's downward pressure over the preceding month, with the market's focus locked on a critical interim analysis scheduled for early in the third quarter of 2026.

The company's lead asset, PMN310, is being evaluated in the Phase 1b PRECISE-AD study. A key differentiator for this therapeutic antibody is its targeted mechanism: it is designed to selectively bind to toxic amyloid-beta oligomers while sparing amyloid plaques in the brain. This approach aims to minimize the risk of severe side effects like ARIA—brain swelling or micro-bleeds—commonly associated with first-generation Alzheimer's therapies. To date, the trial has reported a favorable safety profile with no serious adverse events.

Patient recruitment for the study concluded successfully in December, exceeding initial targets. ProMIS enrolled 144 participants, surpassing the original goal of 128. The company is now transitioning to data analysis as patients complete a six-month observation period. The next major milestone is the completion of these six-month assessments for all patients in the second quarter of 2026.

Financially, the company has extended its runway following a private placement in February that secured gross proceeds of approximately $75.5 million. This capital injection is expected to fund operations through 2027, covering the completion of the current Alzheimer's trial and the continued development of its pipeline programs for ALS and Parkinson's disease.

Beyond PMN310, ProMIS leverages its proprietary EpiSelect™ platform technology to develop targeted antibodies for other neurodegenerative diseases. These earlier-stage programs for ALS and Parkinson's underscore the company's broader strategic focus, though the immediate investor spotlight remains firmly on Alzheimer's.

The upcoming blinded interim analysis in summer 2026 will provide the first significant look at biomarker data and safety, serving as a crucial indicator for the program's potential. The final top-line results from the twelve-month study are expected in early 2027. The company's annual general meeting of shareholders is scheduled for May 20, 2026.